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Abstract
Common genetic variants of FOXP2may contribute to schizophrenia vulnerability, but controversial results have been reported
for this proposal. Here we evaluated the potential impact of the common FOXP2 rs2396753 polymorphism in schizophrenia. It
was previously reported to be part of a risk haplotype for this disease and to have significant effects on gray matter concentration
in the patients. We undertook the first examination into whether rs2396753 affects the brain expression of FOXP2 and a
replication study of earlier neuroimaging findings of the influence of this genetic variant on brain structure. FOXP2 expression
levels were measured in postmortem prefrontal cortex samples of 84 male subjects (48 patients and 36 controls) from the
CIBERSAM Brain and the Stanley Foundation Array Collections. High-resolution anatomical magnetic resonance imaging
was performed on 79 male subjects (61 patients, 18 controls) using optimized voxel-based morphometry. We found differences
in FOXP2 expression and brain morphometry depending on the rs2396753, relating low FOXP2mRNA levels with reduction of
gray matter density. We detected an interaction between rs2396753 and the clinical groups, showing that heterozygous patients
for this polymorphism have gray matter density decrease and low FOXP2 expression comparing with the heterozygous controls.
This study shows the importance of independent replication of neuroimaging genetic studies of FOXP2 as a candidate gene in
schizophrenia. Furthermore, our results suggest that the FOXP2 rs2396753 affects mRNA levels, thus providing new knowledge
about its significance as a potential susceptibility polymorphism in schizophrenia.
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Introduction
The forkhead box P2 (FOXP2) gene was identified as the first
gene involved in the development of speech and language (Lai
et al. 2001). Rare FOXP2 disruptions were reported as the
causative mutations of severe language conditions (reviewed
in Graham &Fisher 2015). Magnetic resonance imaging
(MRI) studies in subjects carrying FOXP2 mutations showed
structural and functional abnormalities in language-related
brain areas (Liégeois et al. 2016; Watkins et al. 2002).
Agreeing, the FOXP2 expression pattern is particularly rele-
vant in the cortex, basal ganglia and other brain areas related
to this human trait (Lai et al. 2003; Reimers-Kipping et al.
2011; Takahashi et al. 2008).
Language impairment and speech disorganization are core
phenomenological characteristics of patients with schizophre-
nia; deficits in the neural organization of language were pro-
posed to affect these patients (DeLisi 2001). This observation
has led to the suggestion of FOXP2 as a potential candidate
gene for schizophrenia vulnerability. In addition, common
genetic variations in FOXP2 have been proposed to contribute
to the etiology of this disease (Sanjuan et al. 2013). In a pre-
liminary study, we found that the common FOXP2 rs2396753
single nucleotide polymorphism (SNP) might be involved in
language disorder vulnerability, including thought disorders
and auditory hallucinations in schizophrenia (Sanjuan et al.
2006). These symptoms are related with structural, functional
and connectivity alterations in brain pathways for language
processing (Li et al. 2009). Using a larger sample of Spanish
descent patients, we identified rs2396753 as part of a risk
haplotype in schizophrenia (Tolosa et al. 2010). The involve-
ment of FOXP2 in schizophrenia vulnerability was further
confirmed in a large sample of the Chinese Han population
(Li et al. 2013). Other authors studying a sample of this pop-
ulation suggested that FOXP2 might play a role in enhancing
the vulnerability to psychotic symptoms in schizophrenia
(Rao et al. 2017). In addition, McCarthy-Jones et al. (2014)
found an interaction between a FOXP2 SNP and parental
child abuse, predicting susceptibility to psychotic auditory
hallucinations. Interestingly, Spaniel and col. (2011) identi-
fied an association between the FOXP2 rs2396753 and gray
matter (GM) concentration changes in schizophrenia patients.
Recently, a common FOXP2 SNP was nominally associated
with phonemic verbal fluency in the Western Australian
Family Study of Schizophrenia (McCarthy et al. 2019).
Genetic variation in FOXP2 has also been associated with
speech and reading related phenotypes in healthy individuals.
It includes differences in activation of the left frontal cortex
during a reading task (Pinel et al. 2012), lateralization of
speech perception (Ocklenburg et al. 2013), differences in
inner speech and speech fluency (Crespi et al. 2017), semantic
fluency (Mozzi et al. 2017) and auditory-motor integration for
vocal pitch regulation (Zhang et al. 2018). Collectively, all
these findings suggest that common polymorphisms of
FOXP2 may be involved in language related phenotypes in
the general population and thereby may contribute to psycho-
pathology and language impairment in neuropsychiatric dis-
orders as schizophrenia. Nonetheless, controversial results
were reported about associations between common variation
of FOXP2 and language in both clinical (McCarthy et al.
2019; Yin et al. 2018) and healthy subjects (Mueller et al.
2016). In addition, the possible influence of these variants in
brain structures in the general population has also been
questioned (Hoogman et al. 2014).
Here, we evaluated whether common polymorphisms of
FOXP2 influence brain structure in schizophrenia. We under-
took the first examination into whether rs2396753 affects the
brain expression of FOXP2. Second, we performed a replica-
tion study of earlier MRI findings of the influence of this SNP
on brain structure (Spaniel et al. 2011), using a larger and
more homogenous sample. As far as we know, this is the first
study that combined structural MRI and brain gene expression




We executed a double approach for examining the relevance
of the common FOXP2 rs2396753 in schizophrenia: FOXP2
expression was measured in postmortem human brain tissues
from the prefrontal cortex (PFC); MRI was performed on 79
unrelated subjects recruited as part of a larger research pro-
gram on schizophrenia. Statistical power of this study is indi-
cated in supplementary material.
Brain tissue samples
PFC samples of schizophrenia patients (n = 25) and control
subjects with no history of psychosis (n = 11) were obtained
from the Brain Collections of the Spanish National Network
for Research in Mental Health CIBERSAM. RNA samples
from the PFC of schizophrenia patients (n = 23) and matched
unaffected controls (n = 25) were obtained from the Array
Collection of the Stanley Medical Research Institute. All do-
nor patients met DSM-IV criteria for schizophrenia. Detailed
description of these samples is shown in Table 1 and the
supplementary material.
Subjects
The patient group included 61 subjects with DSM-IV diagno-
sis for schizophrenia. All patients were assessed with the
Positive and Negative Syndrome Scale (PANSS) (Kay et al.
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1987; Peralta and Cuesta 1994) by a trained evaluator, who
was blind to the genotyping andMRI results. Eighteen healthy
control subjects were also studied. Both groups (Table 2) were
matched by sex (all males), ethnic group (all Caucasian) and
laterality (all right-handed). Detailed description of the inclu-
sion criteria for the MRI study is shown in the supplementary
material.
Genotyping
Genomic DNA (gDNA) was extracted from peripheral blood
leukocytes and from CIBERSAM PFC samples using the
Puregene kit (Gentra Systems, Qiagen). The Array
Collection gDNA was donated by the Stanley Medical
Research Institute. Genotyping ofFOXP2 rs2396753 was per-
formed at the Spanish Genotyping Center of Santiago de
Compostela using the iPLEX Gold technology from
Sequenom. For the CIBERSAM samples, genotyping was
carried out as previously indicated (Tolosa et al. 2010).
Reverse transcription quantitative PCR (RT-qPCR)
Total RNA from the CIBERSAM samples was extracted
using the miRNeasy Mini Kit (Qiagen) according to the
Table 1 Demographic and tissue parameters of the postmortem brain samples
CIBERSAM tissues Patients Controls p
Gender, n males, 25 males, 11 N/A
Age of death, years. Mean (SD) 63.84 (16.17) 71.73 (10.92) 0.15
PMI, hours. Mean (SD) 8.00 (10.08) 8.82 (4.94) 0.80
Brain pH. Mean (SD) 7.12 (0.15) 7.00 (0.20) 0.05
Cause of death 6 Respiratory disease, 12 other medical
conditions, 7 suicide
2 Cardiac, 4 Pneumonia, 5 other
medical conditions
N/A
STANLEY RNA Patients Controls p
Gender, n males, 23 males, 25 N/A
Age of death, years. Mean (SD) 41.35 (8.53) 45.08 (7.82) 0.12
PMI, hours. Mean (SD) 30.13 (16.09) 27.88 (12.33) 0.59
Brain pH. Mean (SD) 6.42 (0.26) 6.66 (0.24) 0.0017*
Cause of death 11 cardiac disease, 7 other medical
conditions, 1 accident, 4 suicide
23 cardiac, 2 other medical conditions N/A
Mean ± standard deviation (SD) are shown for each variable; PMI, postmortem interval; N/A, not applicable; p value obtained when comparing patients
and controls using the unpaired t test; * p < 0.05
Table 2 Demographic and clinical data for subjects who underwent the morphometric MRI examination accounting for FOXP2 rs2396753 genotypes
(AA, AC and CC)
Patients (n = 61) Controls (n = 18)
AA: 3; AC: 13; CC: 2
AA AC CC Total (F, p) a Total (F, p) b
N (%) all males 20 (32.8%) 27 (44.3%) 14 (23.0%) 61 (100%) N/A 18 (100%) N/A
Age, years. Mean (SD) 29.52 (9.20) 32.88 (10.97) 33.25 (9.50) 31.87 (10.06) F = 0.80
p = 0.45
38.24 (7.89) F = 6.09
p = 0.01*
TIV, cm3. Mean (SD) 1082.38 (86.54) 1096.83 (102.63) 1095.35 (99.06) 1091.75 (95.43) F = 0.14
p = 0.87
1139.88 (82.55) F = 3.74
p = 0.06
PANSS Total. Mean (SD) 61.88 (22.94) 68.86 (10.67) 58.92 (21.25) 64.24 (18.15) F = 1.37
p = 0.26
N/A N/A
PANSS Positive. Mean (SD) 15.44 (6.03) 16.64 (5.21) 14.75 (6.27) 15.80 (5.68) F = 0.46
p = 0.63
N/A N/A
PANSS Negative. Mean (SD) 15.19 (6.95) 18.64 (5.63) 14.33 (6.30) 16.50 (6.41) F = 2.37
p = 0.11
N/A N/A
PANSS General. Mean (SD) 31.88 (11.31) 33.59 (5.56) 29.83 (9.92) 31.98 (8.77) F = 0.76
p = 0.47
N/A N/A
Mean ± standard deviation (SD) are shown for each variable; TIV (Total Intracranial Volume); PANSS (Positive and Negative Syndrome Scale); N/A
(not applicable); a statistics (F and p values) comparing AA, AC and CC genotypes in schizophrenia patients using one-way ANOVA test; b statistics (F
and p values) comparing the clinical groups (patients with schizophrenia and healthy control subjects) using one-way ANOVA test. * p < 0.05
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manufacturer’s procedure. RNA from the CIBERSAM and
Stanley samples was converted into cDNA as previously de-
scribed (Gilabert-Juan et al. 2015). Amplification was per-
formed using the Step One Plus Real-Time PCR System on
an Applied Biosystems 7700 (Applied Biosystems) and
SYBR Green PCR master mix (Applied Biosystems). RT-




All subjects underwent an MRI examination on a 3T magnet
(Philips Achieva, Best, The Netherlands). The acquisition pro-
tocol included a 3-dimensional spoiled gradient-echo pulse
sequence (TE = 7.38 ms; TR = 13.18 ms; FA = 8º, NEX = 1,
160 slices, thickness = 1 mm, matrix = 256 × 256, FOV = 240
mm, voxel size = 0.90 × 0.90 × 1 mm).
Data processing
Statistical parametric mapping 8 (SPM8) software (SPM,
Wellcome Institute, London, United Kingdom) and
MATLAB R2015a (The MathWorks, Natick, MA, USA)
were used to process the data. The raw images were evaluated
quantitatively to detect outliers, which were considered as the
images with a high degree of variability (above 3*standard
deviations) from the mean. No images were identified as
outliers.
The voxel-based morphometry (VBM8) and the
Diffeomorphic Anatomical Registrat ion Through
Exponentiated Lie Algebra (DARTEL) method (Ashburner
2007) was used to normalize and to segment the original im-
ages. The GM and white matter (WM) maps obtained after
segmentation were again registered to construct a more accu-
rate diffeomorphic template. The original raw images were
then warped to the DARTEL template using flow fields and
spatial deformations. To preserve the total amount of tissue in
the normalized images, a Jacobian transformation was ap-
plied. Finally, the warped and modulated GM images were
smoothed by a 10 mm full width at half maximum Gaussian
smoothing filter. This value was chosen considering the rela-
tively small number of subjects in each genotype group, which
requires a bigger smoothing kernel to improve signal-to-noise
ratio (Shen and Sterr 2013). Detailed description of quantita-
tive neuroimaging analysis is further indicated in supplemen-
tary material.
Statistical analysis
Tissue features, demographic and clinical data of subjects and
FOXP2 expression were compared using ANOVA and t-test.
Bonferroni test (Rice 1989) was applied for multiple-
comparison correction. In all cases, values of p < 0.05 were
considered statistically significant. Error bars represent stan-
dard deviation (SD).
In neuroimaging, three different statistical models were
created and estimated according to the general linear model
(Friston et al. 1994). The GM probability maps and the two
nuisance variables, age and total intracranial volume (TIV),
were included in these models. First, a two-sample t-test mod-
el was constructed to test for GM differences between patients
and controls. These maps were then binarized (assigning 1 to
those voxels with T values greater than 0 and 0 to the rest) and
used as a restriction-mask in the later analyses. Second, an
ANCOVA model was designed including only the
rs2396753 genotype. This model was used to detect subtle
anatomical GM differences related to the genotype consider-
ing all subjects. Third, a full-factorial ANCOVA model was
tested to assess the GM differences between the subjects by
accounting for two main factors: clinical group (patients ver-
sus controls) and rs2396753 genotype. An extent threshold
filter was applied to consider only those clusters with the
minimum number of contiguous voxels (k) as the expected
number of voxels per cluster provided by SPM8. The statisti-
cal threshold was fixed at p < 0.05 with a family-wise error
(FWE) rate correction for multiple comparisons at the cluster
level.
Results
FOXP2 expression in postmortem brain tissues
Table 3 shows the demographic and tissue-related variables of
the brain samples grouped regarding the rs2396753 geno-
types. These traits showed nonsignificant differences among
the three genotypes in either the patients or controls.
Nonsignificant differences were observed when comparing
patients versus controls, except for the suicide events.
FOXP2 expression was reduced in the PFC of the schizo-
phrenia patients (p = 0.0121; Fig. 1A). In the whole sample,
subjects carrying the AA genotype of rs2396753 showed
higher FOXP2 expression than those with the AC and CC
genotypes (Fig. 1B; p = 0.0451 and p = 0.0281 after the
Bonferroni correction, respectively). The AC genotype exhib-
ited an intermediate expression between both homozygotes,
although the differences were not significant in comparison to
the expression of the CC genotype (Fig. 1B). Overall, these
results indicated a lower expression of the C allele in respect to
the A allele of this SNP. When comparing the FOXP2 expres-
sion in each clinical group, we also observed the differential
expression of both alleles (Fig. 1C). Interestingly, heterozy-
gous samples showed different FOXP2 expression levels in
the patients compared to the controls, although this change
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was nonsignificant. Significance was maintained between the
controls with the AA genotype and the patients with the AC
genotype after the Bonferroni correction (p = 0.0288; Fig.
1C).
Magnetic resonance imaging in patients with
schizophrenia and control subjects
No differences were found between patients and controls for
the TIV (Table 2). However, there was a significant difference
in age between the two clinical groups (p = 0.01); thus, age
was included as a covariate in subsequent statistical analysis.
In the patient group, no differences were detected for age, TIV
or PANSS scores regarding the rs2396753 (Table 2).
We found a significant GM density reduction (p < 0.05
FWE, k = 65) in patients with schizophrenia versus controls
after correcting for the effects of age (F = 6.09; p = 0.02) and




















































































































































































































































































































































































































































































































































































































































































































































































Fig. 1 FOXP2 expression in the prefrontal cortex of male donor subjects
with schizophrenia versus controls (A); accounting for the FOXP2
rs2396753 polymorphism in the total samples (B); taking into
consideration the interaction between this polymorphism and the
clinical groups (C). FOXP2 expression is indicated as fold changes
relative to the control group (A), AA genotype (B) and AA genotype of
the control group (C) considering its expression as 1 in each case.
Asterisk indicates the degree of significance (* p < 0.05) using an
unpaired t test (A) and one-way ANOVA with Bonferroni multiple
comparison tests (B and C). Error bars represent standard deviation
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insular, temporal, frontal and cingulate areas (Fig. 2A;
Supplementary Table 1). Nonsignificant increases in GM
were found in patients compared to controls.
In the whole sample, subjects with the CC genotype
showed a significant decrease in the GM density in respect
to the AA and the AC genotypes in the left precentral gyrus.
There were no differences in age (F = 0.82; p = 0.44) or TIV
(F = 0.65; p = 0.53) between genotype groups (Fig. 2B;
Supplementary Table 2). These results indicated that the C
allele is associated with lower GM density in this brain area
in males. This finding is consistent with the intermediate
values of this trait showed by subjects carrying the AC geno-
type (Fig. 2B).
Next, GM differences were analyzed taken into account the
interaction of the FOXP2 rs2396753 and the clinical group.
Only the comparisons with more than five subjects in each
genotype group were considered to have reliable results. Due
to the reduction of samples per group (AC patients vs. AC
controls), and for exploratory purposes, we applied the FWE
correction for multiple comparisons only at voxel level (not at
cluster level) in this comparison. We found a significant
(p < 0.05, corrected at voxel level, k = 25) GM density reduc-
tion in the AC patients when compared with AC controls.
Neither age (F = 1.54; p = 0.22) nor TIV (F = 2.48; p = 0.12)
showed significant differences between groups. The affected
areas were mainly the frontal, temporal and parietal regions
(Fig. 2C; Supplementary Table 3).
Discussion
In this study, we found a clear concordance between FOXP2
expression and GM density in the brain regarding rs2396753.
Our results suggest that low FOXP2 expression is linked to
GM density reduction in frontal brain regions in males and
that variations in FOXP2 expression in such regions may pro-
voke changes in GM density.
Several studies have related the FOXP2 rs2396753 with
schizophrenia. We previously observed a higher frequency
of the C allele in patients than in controls; this allele was found
to be part of a risk haplotype (Sanjuan et al. 2006). We later
replicated this finding using a larger sample of Spanish de-
scend subjects (Tolosa et al. 2010). In addition, the rs2396753
C allele was correlated with reductions in GM density in sev-
eral brain regions of schizophrenia patients, including the dor-
solateral prefrontal cortex (Spaniel et al. 2011). The GM def-
icits were more extensive in the AC schizophrenia patients,
affecting the PFC, the anterior and median cingulate and the
paracingulate gyri, which suggested that reduction in the GM
concentration in schizophrenia may be driven by the C allele.
Our results replicated these findings and further showed dif-
ferences in FOXP2 expression depending on rs2396753,
linking for the first time low FOXP2 expression to GM den-
sity reductions.
Interestingly, the FOXP2 rs2396753 polymorphism was
also linked to brain activity in language-related areas in
healthy adults. It was associated with performance of the au-
ditory dichotic listening task in a sample of Caucasian de-
scents (Ocklenburg et al. 2013). This result suggested that
common variations in FOXP2 might explain interindividual
variability in language lateralization, a feature that is reduced
in schizophrenia (Bleich-Cohen et al. 2012; Chou et al. 2017;
Ocklenburg et al. 2015). Interindividual variability in the ac-
tivation of the left frontal cortex in healthy subjects was also
correlated with two FOXP2 SNPs in high linkage disequilib-
rium with rs2396753 (Pinel et al. 2012), suggesting that there
may be a continuum between normal and pathological
condi t ions in which FOXP2 might be involved.
Nevertheless, the effect of common genetic variants of
FOXP2 on the variability in brain morphometry is a matter
Fig. 2 Brain imaging data of the male subjects who underwent the MRI
examination. Areas with GM density reductions in patients with
schizophrenia compared with control subjects, p < 0.05 FWE, k = 65
(A); Distribution of the adjusted GM density values in the left
precentral gyrus (-36, 3, 41) concerning the rs2396753 genotypes of
FOXP2 in the overall sample (patients and controls).These values are
shown as arbitrary units (a.u.). Error bars represent standard deviation
(B); Areas with GM density reduction in AC heterozygote patients
compared with AC heterozygote controls in terms of the rs2396753, p
< 0.05, corrected at voxel level, k = 25 (C)
1408 Brain Imaging and Behavior (2021) 15:1403–1411
of debate. Hoogman et al. (2014) did not find association
between common variants in FOXP2 and brain structure var-
iability in a large sample of the general population. It is likely
that common variations in this gene could contribute differen-
tially to variability in neuroanatomy depending on sex and
clinical condition. In this vein, Foxp2 expression was shown
to have a sex-specific spatial and temporal pattern in the de-
veloping mammalian brain, which is influenced by androgens
(Bowers et al. 2014; Fröhlich et al. 2017). Sex differences in
FOXP2 expression were also reported in human cortex sam-
ples from non-diseased donors (Bowers et al. 2013). Thus, sex
should be taken into account when analyzing the effects of
FOXP2 polymorphisms.
The rs2396753 is an intronic SNP located between exons
2b and 3 of FOXP2. Therefore, it might control the FOXP2
expression level in specific cells or tissues. Our results suggest
that rs2396753, or a causal variant in linkage disequilibrium,
participates in FOXP2 regulation, because the FOXP2mRNA
levels are higher in the AA than the CC genotypes (Fig. 1B).
Importantly, the A allele shows putative binding sites for tran-
scription factors belonging to the V$ETSF, V$GABF and
V$ZF35 families, while they are absent in the C allele.
However, this allele has a putative binding site for V$STAF
transcription factors (SNPinspector 2.4 from Genomatix
Software Suite v3.9; Supplementary Table 4). The V$ETSF
family contains members that are positive regulators of tran-
scription (Oikawa and Yamada 2003), meanwhile members of
the V$STAF family function as transcriptional repressors
(Zheng and Yang 2004). Accordingly, we can consider that
transcription factors from these families might contribute to
the different expression levels of the A and C alleles. Detailed
molecular analyses are needed to uncover the regulatory pro-
cess implicated in the expression differences of both alleles.
We found an interesting result concerning the AC geno-
type of the FOXP2 rs2396753. Epigenetic factors, includ-
ing medication, might contribute to the different expres-
sion level of FOXP2 between patients and controls carry-
ing this genotype. Differences of this type were also de-
scribed for the T102C polymorphism of the HTR2A gene
(Abdolmaleky et al. 2011). In this case, the C allele
showed higher expression than that of the T allele, being
more evident in controls than in patients with schizophre-
nia and bipolar disease. The authors found that the HTR2A
expression level was inversely correlated with the degree
of DNA methylation at the HTR2A promoter. Whatever the
cause, the lower expression of FOXP2 in heterozygous
schizophrenia patients than heterozygous controls could
explain the reduced expression of this gene that we found
in PFC of schizophrenia patients (Fig. 1A).
The underlying molecular mechanism by which FOXP2
may be implicated in the decrease in GM density in
schizophrenia patients is unknown andmerits further research.
Abnormalities in GM volumes in cortical regions in schizo-
phrenia were proposed to be caused by impairments in embry-
onic neuronal migration (Jamadar et al. 2011). Interestingly,
several studies described the role ofFoxP2 in neuronal recruit-
ment in Area X, which is associated with vocal learning in
zebra finches (Haesler et al. 2007; Rochefort et al. 2007).
FOXP2 encodes a transcription factor that regulates multiple
downstream targets implicated in development, patterning and
function of the nervous system, including key players of neu-
ral migration (French and Fisher 2014; Vernes et al. 2007,
2011).
Some limitations should be considered in this study. The
small number of controls with the AA and CC genotypes in
our subject sample that underwentMRI prevented comparison
of the effect of these genotypes on GM in schizophrenia pa-
tients versus controls. Additionally we assume that there may
be a potential bias because age in the tissue sample was greater
than in the neuroimaging dataset. Finally, differences in
FOXP2 expression may be found in other brain regions where
this gene is expressed.
In conclusion, we provide a plausible explanation of the
reduction in GM density observed in schizophrenia patients
through differential expression of FOXP2. Our results sup-
ported the previous view that posited a link between the ge-
netic variation of FOXP2 and brain morphometry in
schizophrenia.
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